휴마시스
Financials
Valuation Metrics
휴마시스's Market Cap is ₩675B. At end of 2025 it was ₩1251B. Ranked #1574 of 2,421 in KR market (top 65%), #928 of 1,640 on KOSDAQ (top 57%), #62 of 96 in Health Care Equipment & Services (top 65%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.49B KRW | KR#1,574/2,421 Sec#62/96 |
| Revenue | 31.73B KRW | KR#2,011/2,421 Sec#63/96 |
| Net Income | -26.63B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 335.01B KRW | KR#977/2,421 Sec#20/96 |
| Net Assets | 238.77B KRW | KR#849/2,421 Sec#21/96 |
| Employees | 69 | KR#1,887/2,421 Sec#76/96 |
| Value | ||
| P/B | 0.28x | KR#288/2,421 Sec#2/96 |
| P/S | 2.13x | KR#1,848/2,421 Sec#52/96 |
| Profitability | ||
| ROE | -11.15% | KR#1,967/2,421 Sec#69/96 |
| ROA | -7.95% | KR#2,052/2,421 Sec#72/96 |
| Op. Margin | -33.75% | KR#2,191/2,421 Sec#75/96 |
| Revenue Growth | -15.36% | KR#2,047/2,421 Sec#86/96 |
| Financial Health | ||
| Debt Ratio | 40.30% | KR#796/2,421 Sec#42/96 |
| Total Debt | 15.47B KRW | KR#1,486/2,421 Sec#45/96 |
| Cash | 63.27B KRW | KR#649/2,421 Sec#10/96 |
| Current Ratio | 2.06x | KR#845/2,421 Sec#48/96 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -60.73% | KR#2,210/2,421 Sec#82/96 |
| 1M Return | -1.97% | KR#1,470/2,421 Sec#45/96 |
| From 52W High | -62.22% | KR#1,928/2,421 Sec#67/96 |
| 1Y MDD | -73.14% | KR#2,114/2,421 Sec#78/96 |
| Trading | ||
| Volume | 68,025 shares | KR#972/2,421 Sec#34/96 |
| Trading Value | 185.8M KRW | KR#1,308/2,421 Sec#51/96 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/96 |
| Per Share | ||
| EPS | -1,079 KRW | KR—/2,421 Sec—/96 |
| BPS | 9,677 KRW | KR#1,014/2,421 Sec#21/96 |
Company Info
Humasis, established in 2000 as a manufacturer of in-vitro diagnostic medical devices, was listed on the KOSDAQ market in 2017 after merging with HI No. 2 Special Purpose Acquisition Company. The company specializes in the development and production of POCT immunoassay reagent product lines. Through its subsidiary, Billionths, Humasis also manufactures condoms and medical rubber products and operates an entertainment business. It is pursuing business diversification by obtaining approval for new objectives like mineral development and sales at its 2024 regular general meeting of shareholders and is headquartered in Anyang-si, Gyeonggi-do.